An Integrative Proteomics and Interaction Network-Based Classifier for Prostate Cancer Diagnosis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Jiang, Fu Neng ^a,b   He, Hui Chan ^b   Zhang, Yan Qiong ^c   Yang, Deng Liang ^a   Huang, Jie Hong ^a   Zhu, Yun Xin ^a   Mo, Ru Jun ^b   Chen, Guo ^b   Yang, Sheng Bang ^b   Chen, Yan Ru ^b   Zhong, Wei De ^b   Zhou, Wen Liang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; UPREGULATION; VALIDITY;

AGED; AGED, 80 AND OVER; HISTONE DEACETYLASE 1; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTEIN INTERACTION MAPS; PROTEOMICS; PTEN PHOSPHOHYDROLASE; REPRODUCIBILITY OF RESULTS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878481712     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063941     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Klotz L, (2000) Hormone therapy for patients with prostate carcinoma. Cancer 88: 3009-3014.
3. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E, (2011) Smoking and prostate cancer survival and recurrence. JAMA 305: 2548-2555.
4. Collet B, Guitton N, Sakali S, (2011) Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci 9: 16.
5. Weeks ME, (2010) Urinary proteome profiling using 2D-DIGE and LC-MS/MS. Methods Mol Biol 658: 293-309.
6. Corona G, De Lorenzo E, Elia C, (2010) Differential proteomic analysis of hepatocellular carcinoma. Int J Oncol 36: 93-99.
7. Muto T, Taniguchi H, Kushima R, (2011) Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis. J Proteomics 74: 858-873.
8. Nishimori T, Tomonaga T, Matsushita K, (2006) Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics 6: 1011-1018.
9. Klopfleisch R, Klose P, Weise C, (2010) Proteome of metastatic canine mammary carcinomas: similarities to and differences from human breast cancer. J Proteome Res 9: 6380-6391.
10. Sinclair J, Metodieva G, Dafou D, Gayther SA, Timms JF, (2011) Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging. J Proteomics 74: 451-465.
11. Orenes-Piero E, Cortón M, González-Peramato P, (2007) Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res 6: 4440-4448.
12. Han ZD, Zhang YQ, He HC, Dai QS, Qin GQ, et al. (2012) Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis. Med Oncol 29: 2877-2888.
13. Pang J, Liu WP, Liu XP, (2010) Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res 9: 216-226.
14. Rong Y, Jin D, Hou C, (2010) Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol 10: 68.
15. Zhang Y, Wang S, Li D, Zhnag J, Gu D, et al. (2011) A systems biology-based classifier for hepatocellular carcinoma diagnosis. PLoS One 6: e22426.
16. Tomlins SA, Mehra R, Rhodes DR, Cao X, (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51.
17. Wallace TA, Prueitt RL, Yi M, Howe TM, (2008) Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68: 927-936.
18. Taylor BS, Schultz N, Hieronymus H, Gopalan A, (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
19. Orrù G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A, (2012) Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neurosci Biobehav Rev 36: 1140-1152.
20. Chen L, Xuan J, Riggins RB, Clarke R, Wang Y, (2011) Identifying cancer biomarkers by network-constrained support vector machines. BMC Syst Biol 5: 161.
21. Hsu CW, Chang CC, Lin CJ. A practical guide to support vector classification. Available: http://www.csie.ntu.edu.tw/~cjlin/papers/guide/guide.pdf. Accessed 2013 Apr 15.
22. Baldi P, Brunak S, Chauvin Y, Andersen CA, Nielsen H, (2000) Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 16: 412-424.
23. Zhong WD, Qin GQ, Dai QS, Han ZD, Chen SM, et al. (2012) SOXs in human prostate cancer: implication as progression and prognosis factors. BMC Cancer 12: 248.
24. Jeong H, Mason SP, Barabási AL, Oltvai ZN, (2011) Lethality and centrality in protein networks. Nature 411: 41-42.
25. Wu Z, He B, He J, Mao X, (2012) Up-regulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate In press.
26. Chen J, Shao P, Cao Q, Li P, Li J, et al. (2012) Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLoS One 7: e40817.
27. Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, et al. (2012) Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 25: 1543-1549.
28. Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, et al. (2012) PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 12: 543.
29. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, et al. (2012) An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 118: 6063-71.
30. Kurokawa K, Tanahashi T, Iima T, Yamamoto Y, Akaike Y, et al. (2012) Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol 47: 883-95.
31. Xu Y, Karlsson A, Johansson M, (2011) Identification of genes associated to 2′,2′-difluorodeoxycytidine resistance in HeLa cells with a lentiviral short-hairpin RNA library. Biochem Pharmacol 82: 210-215.
32. Tanaka M, Kato K, Gomi K, Matsumoto M, Kudo H, et al. (2009) Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma. Am J Surg Pathol 33: 1416-1420.
33. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, et al. (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28: 1714-1724.
34. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, et al. (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69: 958-966.
35. Li X, Yin S, Meng Y, Sakr W, Sheng S, (2006) Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Res 66: 9323-9329.
36. Patra SK, Patra A, Dahiya R, (2001) Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287: 705-713.
37. Halkidou K, Gaughan L, Cook S, Leung HY, et al. (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189.
38. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, et al. (2006) NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9: 367-378.